Document and Entity Information
Document and Entity Information Document - shares | 6 Months Ended | |
Jun. 30, 2018 | Jul. 25, 2018 | |
Entity [Abstract] | ||
Entity Registrant Name | TRUPANION, INC. | |
Entity Central Index Key | 1,371,285 | |
Current Fiscal Year End Date | --12-31 | |
Entity Filer Category | Accelerated Filer | |
Document Type | 10-Q | |
Document Period End Date | Jun. 30, 2018 | |
Document Fiscal Year Focus | 2,018 | |
Document Fiscal Period Focus | Q2 | |
Amendment Flag | false | |
Entity Common Stock, Shares Outstanding | 32,776,401 |
Consolidated Statement of Opera
Consolidated Statement of Operations - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
Income Statement [Abstract] | ||||
Revenue | $ 73,392 | $ 58,275 | $ 143,152 | $ 113,004 |
Cost of Revenue [Abstract] | ||||
Veterinary invoice expense | 51,780 | 41,009 | 101,893 | 80,196 |
Other cost of revenue | 9,259 | 6,915 | 17,842 | 13,302 |
Gross profit | 12,353 | 10,351 | 23,417 | 19,506 |
Operating Expenses [Abstract] | ||||
Technology and Development | 2,298 | 2,322 | 4,462 | 4,725 |
General and administrative | 4,610 | 4,245 | 9,068 | 8,257 |
Sales and marketing | 5,702 | 4,372 | 11,640 | 8,461 |
Total operating expenses | 12,610 | 10,939 | 25,170 | 21,443 |
Operating loss | (257) | (588) | (1,753) | (1,937) |
Interest expense | 332 | 109 | 551 | 246 |
Other (income) expense, net | (303) | (1,112) | (443) | (1,140) |
Income (Loss) before income taxes | (286) | 415 | (1,861) | (1,043) |
Income tax expense (benefit) | 91 | 4 | (4) | 28 |
Net (loss) income | $ (377) | $ 411 | $ (1,857) | $ (1,071) |
Net income (loss) per share [Abstract] | ||||
Earnings Per Share, Basic and Diluted | $ (0.01) | $ 0.01 | $ (0.06) | $ (0.04) |
Weighted Average Number of Shares Outstanding, Basic | 30,721,037 | 29,510,907 | 30,485,121 | 29,383,502 |
Weighted Average Number of Shares Outstanding, Diluted | 30,721,037 | 32,734,624 | 30,485,121 | 29,383,502 |
Consolidated Statement of Compr
Consolidated Statement of Comprehensive Income Statement - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
Statement of Comprehensive Income [Abstract] | ||||
Net (loss) income | $ (377) | $ 411 | $ (1,857) | $ (1,071) |
Foreign currency translation adjustments | (129) | 111 | (319) | 123 |
Net unrealized gain on available-for-sale debt securities | 15 | 16 | 0 | 9 |
Other comprehensive (loss) income, net of taxes | (114) | 127 | (319) | 132 |
Comprehensive Income (Loss) | $ (491) | $ 538 | $ (2,176) | $ (939) |
Consolidated Balance Sheet
Consolidated Balance Sheet - USD ($) $ in Thousands | Jun. 30, 2018 | Dec. 31, 2017 |
Assets [Abstract] | ||
Cash and cash equivalents | $ 95,424 | $ 25,706 |
Short-term Investments | 42,802 | 37,590 |
Accounts and other receivables | 28,552 | 20,367 |
Prepaid expenses and other assets | 6,890 | 2,895 |
Total current assets | 173,668 | 86,558 |
Restricted Cash | 1,400 | 600 |
Long-Term Investments, at fair value | 3,311 | 3,237 |
Property and equipment, net | 8,208 | 7,868 |
Intangible assets, net | 5,158 | 4,972 |
Other Long-Term Assets | 2,554 | 2,624 |
Total assets | 194,299 | 105,859 |
Liabilities and Equity [Abstract] | ||
Accounts payable | 2,373 | 2,716 |
Accrued liabilities and other current liabilities | 10,424 | 7,660 |
Reserve for veterinary invoices | 13,996 | 12,756 |
Deferred Revenue | 30,339 | 22,734 |
Total current liabilities | 57,132 | 45,866 |
Long-term debt | 18,628 | 9,324 |
Deferred tax liabilities | 1,002 | 1,002 |
Other liabilities | 1,285 | 1,233 |
Total liabilities | 78,047 | 57,425 |
Common stock | 0 | 0 |
Preferred Stock | 0 | 0 |
Additional paid-in capital | 207,505 | 134,511 |
Accumulated other comprehensive loss | (411) | (92) |
Accumulated deficit | (84,641) | (82,784) |
Treasury stock, at cost | (6,201) | (3,201) |
Stockholders' Equity Attributable to Parent | 116,252 | 48,434 |
Total liabilities and stockholders' equity | $ 194,299 | $ 105,859 |
Consolidated Balance Sheet Cond
Consolidated Balance Sheet Condensed Consolidated Balance Sheet Parentheticals - $ / shares | Jun. 30, 2018 | Dec. 31, 2017 |
Common Stock [Member] | ||
Common Stock, Par or Stated Value Per Share | $ 0.00001 | $ 0.00001 |
Common Stock, Shares Authorized | 100,000,000 | 100,000,000 |
Common Stock, Shares, Issued | 33,475,275 | 30,778,796 |
Common Stock, Shares, Outstanding | 32,719,290 | 30,121,496 |
Preferred Stock [Member] | ||
Preferred Stock, Par or Stated Value Per Share | $ 0.00001 | $ 0.00001 |
Preferred Stock, Shares Authorized | 10,000,000 | 10,000,000 |
Preferred Stock, Shares Issued | 0 | 0 |
Preferred Stock, Shares Outstanding | 0 | 0 |
Treasury Stock [Member] | ||
Treasury Stock, Shares | 755,985 | 657,300 |
Consolidated Statement of Cash
Consolidated Statement of Cash Flows - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
Net Cash Provided by Operating Activities [Abstract] | ||
Net loss | $ (1,857) | $ (1,071) |
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] | ||
Depreciation and Amortization | 1,891 | 2,113 |
Stock-based compensation expense | 2,254 | 1,669 |
Gain (Loss) on Sale of Equity Investments | 0 | 1,036 |
Other, Net | 38 | 56 |
Increase (Decrease) in Operating Assets [Abstract] | ||
Accounts and other receivables | (8,168) | (6,968) |
Prepaid expenses and other assets | (4,068) | (183) |
Accounts Payable, Accrued Liabilities, and Other Liabilities | 2,567 | 913 |
Claims Reserve | 1,293 | 1,259 |
Deferred revenue | 7,661 | 6,929 |
Net cash provided by operating activities | 1,611 | 3,681 |
Payments to Acquire Investments | 20,386 | 14,895 |
Net Cash Provided by Investing Activities [Abstract] | ||
Maturities of Investment Securities | 15,015 | 11,712 |
Proceeds from Sale of Equity Method Investments | 0 | 1,402 |
Purchases of property and equipment | (2,370) | (1,264) |
Other Investments | 113 | (2,753) |
Proceeds from Issuance or Sale of Equity | 65,886 | 0 |
Net cash used in investing activities | (7,628) | (5,798) |
Net Cash Provided by Financing Activities [Abstract] | ||
Proceeds from Issuance or Sale of Equity | 65,886 | 0 |
Proceeds from exercise of stock options | 1,656 | 1,647 |
Proceeds from Warrant Exercises | 300 | 0 |
Proceeds from Debt financing, net of financing fees | 9,250 | 1,459 |
Proceeds from (Payments for) Other Financing Activities | (356) | (203) |
Net cash provided by financing activities | 76,736 | 2,903 |
Effect of foreign exchange rate changes on cash, cash equivalents, and restricted cash, net | (201) | 181 |
Net Increase in Cash, Cash Equivalents, and Restricted Cash | 70,518 | 967 |
Cash, Cash Equivalents, and Restricted Cash at beginning of period | 26,306 | 24,237 |
Cash, Cash Equivalents, and Restricted Cash, End of Period | 96,824 | 25,204 |
Supplemental Cash Flow Information [Abstract] | ||
Purchases of property and equipment included in accounts payable and accrued liabilities | 153 | 352 |
Property and Equipment Acquired Under Capital Leases | 0 | 66 |
Redemption of Warrants Non-Cash; Common Stock | $ 3,000 | $ 0 |
Nature of Operations and Summar
Nature of Operations and Summary of Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2018 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Nature of Operations and Summary of Significant Accounting Policies | Nature of Operations and Significant Accounting Policies Description of Business and Basis of Presentation Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the Company) provides medical insurance for cats and dogs throughout the United States, Canada and Puerto Rico. The financial data as of December 31, 2017 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive (loss) income, and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S Securities and Exchange Commission (SEC) on February 13, 2018 (the 2017 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2017 10-K. Operating results for the three and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period. Follow-on Public Offering In June 2018, the Company completed a follow-on public offering (the June 2018 follow-on public offering) whereby the Company sold 2,090,909 shares of common stock (inclusive of 272,727 shares of common stock sold by the Company pursuant to the full exercise of the underwriters' option to purchase additional shares) at a price to the public of $33.00 per share. The Company received aggregate net proceeds from the June 2018 follow-on public offering of $65.9 million , after deducting underwriting discounts and commissions and offering expenses payable by the Company. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2017 10-K for additional discussion of these estimates and assumptions. Accumulated Other Comprehensive Loss There were no reclassifications out of accumulated other comprehensive loss during the three and six months ended June 30, 2018 and 2017 . Income Taxes On December 22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act (Tax Act), making broad and complex changes to the Internal Revenue Code. The Company has made significant judgments and estimates in accordance with its interpretation of the Tax Act. As additional guidance on the Tax Act becomes available, the Company may adjust its interpretation of the requirements, which may result in a material change to income tax benefit or expense in the period in which the adjustment is made. Recent Accounting Pronouncements |
Net Loss per Share
Net Loss per Share | 6 Months Ended |
Jun. 30, 2018 | |
Earnings Per Share, Basic and Diluted [Abstract] | |
Earnings Per Share [Text Block] | Net (Loss) Income per Share Basic net (loss) income per share is computed using the weighted average number of shares of common stock outstanding during the period. Diluted net (loss) income per share is calculated using the weighted average number of shares of common stock plus, when dilutive, potential common shares outstanding using the treasury-stock method. Potential common shares outstanding include stock options, unvested restricted stock awards and restricted stock units, and warrants. The components of basic and diluted earnings per share were as follows: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Basic earnings per share: Net (loss) income $ (377 ) $ 411 $ (1,857 ) $ (1,071 ) Shares used in computation: Weighted average common shares outstanding 30,721,037 29,510,907 30,485,121 29,383,502 Basic earnings per share $ (0.01 ) $ 0.01 $ (0.06 ) $ (0.04 ) Diluted earnings per share: Net (loss) income $ (377 ) $ 411 $ (1,857 ) $ (1,071 ) Shares used in computation: Weighted average common shares outstanding 30,721,037 29,510,907 30,485,121 29,383,502 Stock options — 2,511,012 — — Restricted stock awards and units — 351,668 — — Warrants — 361,037 — — Weighted average number of shares 30,721,037 32,734,624 30,485,121 29,383,502 Diluted earnings per share $ (0.01 ) $ 0.01 $ (0.06 ) $ (0.04 ) The following potentially dilutive equity securities were not included in the diluted earnings per common share calculation because they would have had an antidilutive effect: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Stock options 3,696,242 1,035,163 3,696,242 4,207,577 Restricted stock awards and restricted stock units 555,984 — 555,984 351,668 Warrants 480,000 — 480,000 810,000 |
Investment Securities (Notes)
Investment Securities (Notes) | 6 Months Ended |
Jun. 30, 2018 | |
Investments [Abstract] | |
Investment [Text Block] | Investment Securities The amortized cost, gross unrealized holding gains and losses, fair value of long-term investments, which are classified as available-for-sale, and fair value of short-term investments by major security type and class of security were as follows as of June 30, 2018 and December 31, 2017 (in thousands): Amortized Gross Gross Fair As of June 30, 2018 Available-for-sale: Foreign deposits $ 2,311 $ — $ — $ 2,311 Municipal bond 1,000 — — 1,000 $ 3,311 $ — $ — $ 3,311 Short-term investments: U.S. Treasury securities $ 6,231 $ — $ (2 ) $ 6,229 Certificates of deposit 439 — — 439 U.S. government funds 36,132 — — 36,132 $ 42,802 $ — $ (2 ) $ 42,800 Amortized Gross Gross Fair As of December 31, 2017 Available-for-sale: Foreign deposits $ 2,237 $ — $ — $ 2,237 Municipal bond 1,000 — — 1,000 $ 3,237 $ — $ — $ 3,237 Short-term investments: U.S. Treasury securities $ 5,783 $ — $ (4 ) $ 5,779 Certificates of deposit 690 1 — 691 U.S. government funds 31,117 — — 31,117 $ 37,590 $ 1 $ (4 ) $ 37,587 Maturities of debt securities classified as available-for-sale were as follows (in thousands): June 30, 2018 Amortized Fair Available-for-sale: Due after one year through five years $ 2,311 $ 2,311 Due after five years through ten years 1,000 1,000 $ 3,311 $ 3,311 |
Investments [Text Block] | The amortized cost, gross unrealized holding gains and losses, fair value of long-term investments, which are classified as available-for-sale, and fair value of short-term investments by major security type and class of security were as follows as of June 30, 2018 and December 31, 2017 (in thousands): Amortized Gross Gross Fair As of June 30, 2018 Available-for-sale: Foreign deposits $ 2,311 $ — $ — $ 2,311 Municipal bond 1,000 — — 1,000 $ 3,311 $ — $ — $ 3,311 Short-term investments: U.S. Treasury securities $ 6,231 $ — $ (2 ) $ 6,229 Certificates of deposit 439 — — 439 U.S. government funds 36,132 — — 36,132 $ 42,802 $ — $ (2 ) $ 42,800 Amortized Gross Gross Fair As of December 31, 2017 Available-for-sale: Foreign deposits $ 2,237 $ — $ — $ 2,237 Municipal bond 1,000 — — 1,000 $ 3,237 $ — $ — $ 3,237 Short-term investments: U.S. Treasury securities $ 5,783 $ — $ (4 ) $ 5,779 Certificates of deposit 690 1 — 691 U.S. government funds 31,117 — — 31,117 $ 37,590 $ 1 $ (4 ) $ 37,587 |
Fair Value
Fair Value | 6 Months Ended |
Jun. 30, 2018 | |
Fair Value Disclosures [Abstract] | |
Fair Value Disclosures [Text Block] | Fair Value Investments The following table summarizes, by major security type, the Company's assets that are measured at fair value on a recurring basis, and placement within the fair value hierarchy (in thousands): As of June 30, 2018 Fair Value Level 1 Level 2 Assets Restricted cash $ 1,400 $ 1,400 $ — Foreign deposits 2,311 2,311 — Municipal bond 1,000 — 1,000 Money market funds 45,420 45,420 — Total $ 50,131 $ 49,131 $ 1,000 As of December 31, 2017 Fair Value Level 1 Level 2 Assets Restricted cash $ 600 $ 600 $ — Foreign deposits 2,237 2,237 — Municipal bond 1,000 — 1,000 Money market funds 5,167 5,167 — Total $ 9,004 $ 8,004 $ 1,000 The Company measures the fair value of restricted cash, foreign deposits, and money market funds based on quoted prices in active markets for identical assets. The fair value of the municipal bond is based on either recent trades in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. Short-term investments are carried at amortized cost and the fair value is disclosed in Note 3, Investment Securities. The fair value of these investments is determined in the same manner as for available-for-sale securities and is considered a Level 1 measurement. Fair Value Disclosures As of June 30, 2018 and December 31, 2017, the Company's other long-term assets balance included a $2.5 million note receivable, recorded at its estimated collectible amount. The Company estimates that the carrying value of the note receivable approximates its fair value. The estimated fair value represents a Level 3 measurement within the fair value hierarchy, and is based on market interest rates and the assessed creditworthiness of the third party. The Company estimates the fair value of its long-term debt based upon rates currently available to the Company for debt with similar terms and remaining maturities. This is a Level 3 measurement. Based upon the terms of the debt, the carrying amount of long-term debt approximated fair value at June 30, 2018 and December 31, 2017 |
Debt
Debt | 6 Months Ended |
Jun. 30, 2018 | |
Debt Disclosure [Abstract] | |
Debt Disclosure [Text Block] | Debt On June 28, 2018, the Company amended its credit agreement, increasing its borrowing capacity from $30.0 million to $50.0 million , extending the maturity date to June 2021, and increasing the required amount of restricted cash. The facility is secured by any and all interests in the Company's assets that are not otherwise restricted. Interest on the revolving line of credit is payable monthly at the greater of 4.5%, or 1.25% plus the prime rate ( 6.25% at June 30, 2018 ). The credit agreement includes other ancillary services and letters of credit of up to $4.5 million , and requires a deposit of restricted cash of $1.4 million . As of June 30, 2018 , the Company was in compliance with all financial and non-financial covenants required by the credit agreement. Borrowings on the revolving line of credit are limited to the lesser of $50.0 million and the total amount of cash and securities held by the Company's insurance subsidiaries (American Pet Insurance Company and Wyndham Insurance Company (SAC) Limited Segregated Account AX). As of June 30, 2018 , available borrowing capacity on the line of credit was $20.2 million , with an outstanding balance of $1.9 million for ancillary services and letters of credit, and borrowings under the facility of $18.8 million , recorded net of financing fees of $0.2 million |
Commitment and Contingencies
Commitment and Contingencies | 6 Months Ended |
Jun. 30, 2018 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies Disclosure [Text Block] | Commitments and Contingencies Litigation From time to time, the Company is subject to litigation matters and claims arising from the ordinary course of business. The Company records a provision for a liability relating to legal matters when it is both probable that a material liability has been incurred and the amount of the loss can be reasonably estimated. At this time, the Company does not believe any such matters to be material individually or in the aggregate. These views are subject to change following the outcome of future events or the results of future developments. Agreement for the Purchase of Corporate Headquarters In June 2018, the Company entered into a Real Estate Purchase and Sale Agreement (Real Estate Purchase Agreement) with Benaroya Capital Company, L.L.C to purchase certain properties (Properties) as defined within the Real Estate Purchase Agreement, located at 6100 Fourth Avenue South, Seattle, Washington. The purchase price will consist of $55.0 million in cash and 303,030 shares of common stock. The Company currently leases a portion of the Properties for use as its corporate headquarters and has recognized $1.0 million of rent expense under this lease for the six months ended June 30, 2018. Pursuant to this agreement, in June 2018, the Company made a $3.3 million |
Claims Reserve
Claims Reserve | 6 Months Ended |
Jun. 30, 2018 | |
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] | |
Supplementary Insurance Information, for Insurance Companies Disclosure [Text Block] | Reserve for Veterinary Invoices The reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary invoices that are dated as of, or prior to, its balance sheet date. The reserve also includes the Company's estimate of related internal processing costs. The reserve estimate involves actuarial projections, and is based on management's assessment of facts and circumstances currently known, and assumptions about anticipated patterns, including expected future trends in the number of veterinary invoices the Company will receive and the average cost of those veterinary invoices. The reserve is made for each of the Company's segments, subscription and other business, and are continually refined as the Company receives and pays veterinary invoices. Changes in management's assumptions and estimates may have a relatively large impact to the reserve and associated expense. Reserve for veterinary invoices Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands): Six Months Ended June 30, Subscription 2018 2017 Reserve at beginning of year $ 11,059 $ 8,538 Veterinary invoices during the period related to: Current year 91,464 74,244 Prior years 119 (257 ) Total veterinary invoice expense 91,583 73,987 Amounts paid during the period related to: Current year 80,841 65,549 Prior years 9,256 7,138 Total paid 90,097 72,687 Non-cash expenses 333 229 Reserve at end of period $ 12,212 $ 9,609 The Company's reserve for the subscription business segment increased from $11.1 million at December 31, 2017 to $12.2 million at June 30, 2018 . This change was comprised of $91.6 million in expense recorded during the period less $90.1 million in payments of veterinary invoices. The $91.6 million in veterinary invoice expense incurred includes an adjustment of $0.1 million to the reserves relating to prior years, which is the result of ongoing analysis of recent payment trends. For the six months ended June 30, 2017 , the Company decreased prior year reserves by $0.3 million as a result of analysis of payment trends. Summarized below are the changes in total liability for the Company's other business segment (in thousands): Six Months Ended June 30, Other Business 2018 2017 Reserve at beginning of year $ 1,697 $ 983 Veterinary invoices during the period related to: Current year 10,589 6,337 Prior years (279 ) (128 ) Total veterinary invoice expense 10,310 6,209 Amounts paid during the period related to: Current year 8,916 5,217 Prior years 1,307 764 Total paid 10,223 5,981 Non-cash expenses — — Reserve at end of period $ 1,784 $ 1,211 The Company’s reserve for the other business segment increased from $1.7 million at December 31, 2017 to $1.8 million at June 30, 2018 . This change was comprised of $10.3 million in expense recorded during the period less $10.2 million in payments of veterinary invoices. The $10.3 million in veterinary invoice expense incurred includes a reduction of $0.3 million to the reserves relating to prior years, which is the result of ongoing analysis of recent payment trends. For the six months ended June 30, 2017 , the Company decreased prior year reserves by $0.1 million as a result of analysis of payment trends. Reserve for veterinary invoices, by year of occurrence In the following tables, the reserve for veterinary invoices for each segment is presented as the amount (in thousands) by year the veterinary invoice relates to, referred to as the year of occurrence. Subscription As of June 30, 2018 Year of Occurrence 2016 $ 386 2017 1,537 2018 10,289 $ 12,212 Other Business As of June 30, 2018 Year of Occurrence 2017 $ 110 2018 1,674 $ 1,784 |
Stock-based Compensation
Stock-based Compensation | 6 Months Ended |
Jun. 30, 2018 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | Stock-Based Compensation and Stockholders' Equity Stock-based Compensation Stock-based compensation expense includes stock options, restricted stock awards, and restricted stock units granted to employees and non-employees and has been reported in the Company’s consolidated statements of operations depending on the function performed by the employee or non-employee. Stock-based compensation expense recognized in the consolidated statements of operations was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Veterinary invoice expense $ 148 $ 89 $ 268 $ 159 Other cost of revenue 104 60 181 103 Technology and development 60 59 109 109 General and administrative 625 482 1,074 913 Sales and marketing 349 198 622 385 Total stock-based compensation $ 1,286 $ 888 $ 2,254 $ 1,669 As of June 30, 2018 , for all employees, the Company had 683,338 unvested stock options and 555,984 unvested restricted stock awards and restricted stock units that are expected to vest. Stock-based compensation expense of $4.3 million related to unvested stock options and $8.4 million related to unvested restricted stock awards and restricted stock units, each expected to be recognized over a weighted average period of approximately 2.3 years. Stock Options A summary of the Company's stock option activity is as follows: Number Of Options Weighted Average Exercise Price per Share Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2017 4,006,399 $ 7.16 $ 88,578 Granted — — Exercised (262,967 ) 6.30 6,681 Forfeited (47,190 ) 15.44 Outstanding as of June 30, 2018 3,696,242 $ 7.12 $ 116,370 Exercisable as of June 30, 2018 3,008,570 $ 5.22 $ 100,432 As of June 30, 2018 , stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 4.8 years and 4.1 years, respectively. Restricted Stock Awards and Restricted Stock Units A summary of the Company’s restricted stock award and restricted stock unit activity is as follows: Number of Weighted Average Unvested shares as of December 31, 2017 256,842 $ 4.77 Granted 323,358 27.87 Vested (12,603 ) 26.85 Forfeited (11,613 ) 28.36 Unvested shares as of June 30, 2018 555,984 $ 18.27 Stockholders’ Equity In the June 2018 follow-on public offering, the Company sold 2,090,909 shares of common stock (inclusive of 272,727 shares of common stock sold by the Company pursuant to the full exercise of the underwriters' option to purchase additional shares) at a price to the public of $33.00 per share. The Company received aggregate net proceeds of $65.9 million , after deducting underwriting discounts and commissions and offering expenses payable by the Company. During the six months ended June 30, 2018, 330,000 of the Company's outstanding warrants were exercised. As of June 30, 2018, warrants to purchase 480,000 shares of the Company's common stock at $10.00 |
Segments
Segments | 6 Months Ended |
Jun. 30, 2018 | |
Segment Reporting [Abstract] | |
Segment Reporting Disclosure [Text Block] | Segments The Company has two segments: subscription business and other business. The subscription business segment includes monthly subscription fees related to the Company’s medical insurance which is marketed directly to consumers, while the other business segment includes all other business that is not directly marketed to consumers. The chief operating decision maker uses two measures to evaluate segment performance: revenue and gross profit. Additionally, other operating expenses, such as sales and marketing expenses, are allocated to each segment and evaluated when material. Interest and other expenses and income taxes are not allocated to the segments, nor included in the measure of segment profit or loss. The Company does not analyze discrete segment balance sheet information related to long-term assets. Revenue and gross profit of the Company’s segments were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Revenue: Subscription business $ 63,867 $ 52,641 $ 125,384 $ 102,870 Other business 9,525 5,634 17,768 10,134 73,392 58,275 143,152 113,004 Veterinary invoice expense: Subscription business 46,446 37,664 91,583 73,987 Other business 5,334 3,345 10,310 6,209 51,780 41,009 101,893 80,196 Other cost of revenue: Subscription business 5,887 4,927 11,764 9,850 Other business 3,372 1,988 6,078 3,452 9,259 6,915 17,842 13,302 Gross profit: Subscription business 11,534 10,050 22,037 19,033 Other business 819 301 1,380 473 12,353 10,351 23,417 19,506 Technology and development 2,298 2,322 4,462 4,725 General and administrative 4,610 4,245 9,068 8,257 Sales and marketing: Subscription business 5,614 4,309 11,465 8,350 Other business 88 63 175 111 5,702 4,372 11,640 8,461 Operating loss $ (257 ) $ (588 ) $ (1,753 ) $ (1,937 ) The following table presents the Company’s revenue by geographic region of the member (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 United States $ 59,431 $ 47,306 $ 115,440 $ 91,440 Canada 13,961 10,969 27,712 21,564 Total revenue $ 73,392 $ 58,275 $ 143,152 $ 113,004 Substantially all of the Company’s long-lived assets were located in the United States as of June 30, 2018 and December 31, 2017 |
Subsequent Events (Notes)
Subsequent Events (Notes) | 6 Months Ended |
Jun. 30, 2018 | |
Subsequent Events [Abstract] | |
Subsequent Events [Text Block] | Subsequent Events On July 18, 2018, the Company purchased an equity interest, as a limited partner, in a privately held corporation for approximately $3.0 million . The Company has a contingent commitment to purchase an additional $4.0 million of equity for eighteen months following the initial investment. In conjunction with the investment, the Company has extended a revolving line of credit with a maximum borrowing capacity of $2.5 million |
Nature of Operations and Summ17
Nature of Operations and Summary of Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2018 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Business Description and Basis of Presentation [Text Block] | Description of Business and Basis of Presentation Trupanion, Inc. (collectively with its wholly-owned subsidiaries, the Company) provides medical insurance for cats and dogs throughout the United States, Canada and Puerto Rico. The financial data as of December 31, 2017 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive (loss) income, and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S Securities and Exchange Commission (SEC) on February 13, 2018 (the 2017 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2017 10-K. Operating results for the three and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the full fiscal year or any other interim period. Follow-on Public Offering In June 2018, the Company completed a follow-on public offering (the June 2018 follow-on public offering) whereby the Company sold 2,090,909 shares of common stock (inclusive of 272,727 shares of common stock sold by the Company pursuant to the full exercise of the underwriters' option to purchase additional shares) at a price to the public of $33.00 per share. The Company received aggregate net proceeds from the June 2018 follow-on public offering of $65.9 million |
Basis of Accounting, Policy [Policy Text Block] | The financial data as of December 31, 2017 was derived from the Company's audited consolidated financial statements. The accompanying unaudited interim consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) and, in management's opinion, have been prepared on the same basis as the audited financial statements and include all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company's financial position, results of operations, comprehensive (loss) income, and cash flows for the interim periods. These unaudited interim consolidated financial statements should be read in conjunction with the Company’s audited financial statements included in the Company’s Annual Report on Form 10-K, filed with the U.S Securities and Exchange Commission (SEC) on February 13, 2018 (the 2017 10-K). The Company's accounting policies are described in Note 1 to the audited financial statements included in the 2017 10-K. Operating results for the three and six months ended June 30, 2018 |
Use of Estimates [Policy Text Block] | Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from such estimates. See Note 1 to the audited financial statements included in the 2017 10-K for additional discussion of these estimates and assumptions. |
Comprehensive Income, Policy [Policy Text Block] | Accumulated Other Comprehensive Loss There were no reclassifications out of accumulated other comprehensive loss during the three and six months ended June 30, 2018 and 2017 |
Income Tax, Policy [Policy Text Block] | Income TaxesOn December 22, 2017, the U.S. government enacted the Tax Cuts and Jobs Act (Tax Act), making broad and complex changes to the Internal Revenue Code. The Company has made significant judgments and estimates in accordance with its interpretation of the Tax Act. As additional guidance on the Tax Act becomes available, the Company may adjust its interpretation of the requirements, which may result in a material change to income tax benefit or expense in the period in which the adjustment is made. |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting PronouncementsIn February 2016, the Financial Accounting Standards Board (FASB) issued an Accounting Standards Update (ASU) amending the lease presentation guidance. The ASU requires organizations that lease assets to recognize the rights and obligations created by those leases on the consolidated balance sheets. This ASU is effective for fiscal years beginning after December 15, 2018 including interim periods within that reporting period, with early adoption permitted. The Company has determined this guidance will require recognition of a lease liability and corresponding asset on the consolidated balance sheets equal to the present value of minimum lease payments. The carrying amount of the asset is derived from the amount of the lease liability at the end of each reporting period. The Company plans to adopt this guidance as of January 1, 2019, and is in the process of evaluating the impact on its consolidated financial statements. |
Fair Value Notes Receivable (Po
Fair Value Notes Receivable (Policies) | 6 Months Ended |
Jun. 30, 2018 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Loans, Notes, Trade and Other Receivables Disclosure [Text Block] | As of June 30, 2018 and December 31, 2017, the Company's other long-term assets balance included a $2.5 million note receivable, recorded at its estimated collectible amount. The Company estimates that the carrying value of the note receivable approximates its fair value. The estimated fair value represents a Level 3 measurement within the fair value hierarchy, and is based on market interest rates and the assessed creditworthiness of the third party. The Company estimates the fair value of its long-term debt based upon rates currently available to the Company for debt with similar terms and remaining maturities. This is a Level 3 measurement. Based upon the terms of the debt, the carrying amount of long-term debt approximated fair value at June 30, 2018 and December 31, 2017 |
Fair Value Fair Value (Policies
Fair Value Fair Value (Policies) | 6 Months Ended |
Jun. 30, 2018 | |
Fair Value Disclosures [Abstract] | |
Fair Value of Financial Instruments, Policy [Policy Text Block] | The Company measures the fair value of restricted cash, foreign deposits, and money market funds based on quoted prices in active markets for identical assets. The fair value of the municipal bond is based on either recent trades in inactive markets or quoted market prices of similar instruments and other significant inputs derived from or corroborated by observable market data. Short-term investments are carried at amortized cost and the fair value is disclosed in Note 3, Investment Securities. The fair value of these investments is determined in the same manner as for available-for-sale securities and is considered a Level 1 measurement. |
Claims Reserve Claims Reserve (
Claims Reserve Claims Reserve (Policies) | 6 Months Ended |
Jun. 30, 2018 | |
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] | |
Liability Reserve Estimate, Policy [Policy Text Block] | Reserve for Veterinary InvoicesThe reserve for veterinary invoices is an estimate of the future amount the Company will pay for veterinary invoices that are dated as of, or prior to, its balance sheet date. The reserve also includes the Company's estimate of related internal processing costs. The reserve estimate involves actuarial projections, and is based on management's assessment of facts and circumstances currently known, and assumptions about anticipated patterns, including expected future trends in the number of veterinary invoices the Company will receive and the average cost of those veterinary invoices. The reserve is made for each of the Company's segments, subscription and other business, and are continually refined as the Company receives and pays veterinary invoices. Changes in management's assumptions and estimates may have a relatively large impact to the reserve and associated expense. |
Segments Segments (Policies)
Segments Segments (Policies) | 6 Months Ended |
Jun. 30, 2018 | |
Segment Reporting [Abstract] | |
Segment Reporting, Policy [Policy Text Block] | The Company has two segments: subscription business and other business. The subscription business segment includes monthly subscription fees related to the Company’s medical insurance which is marketed directly to consumers, while the other business segment includes all other business that is not directly marketed to consumers. The chief operating decision maker uses two measures to evaluate segment performance: revenue and gross profit. Additionally, other operating expenses, such as sales and marketing expenses, are allocated to each segment and evaluated when material. Interest and other expenses and income taxes are not allocated to the segments, nor included in the measure of segment profit or loss. The Company does not analyze discrete segment balance sheet information related to long-term assets. |
Net Loss per Share (Tables)
Net Loss per Share (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Earnings Per Share, Basic and Diluted [Abstract] | |
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | The components of basic and diluted earnings per share were as follows: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Basic earnings per share: Net (loss) income $ (377 ) $ 411 $ (1,857 ) $ (1,071 ) Shares used in computation: Weighted average common shares outstanding 30,721,037 29,510,907 30,485,121 29,383,502 Basic earnings per share $ (0.01 ) $ 0.01 $ (0.06 ) $ (0.04 ) Diluted earnings per share: Net (loss) income $ (377 ) $ 411 $ (1,857 ) $ (1,071 ) Shares used in computation: Weighted average common shares outstanding 30,721,037 29,510,907 30,485,121 29,383,502 Stock options — 2,511,012 — — Restricted stock awards and units — 351,668 — — Warrants — 361,037 — — Weighted average number of shares 30,721,037 32,734,624 30,485,121 29,383,502 Diluted earnings per share $ (0.01 ) $ 0.01 $ (0.06 ) $ (0.04 ) |
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | The following potentially dilutive equity securities were not included in the diluted earnings per common share calculation because they would have had an antidilutive effect: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Stock options 3,696,242 1,035,163 3,696,242 4,207,577 Restricted stock awards and restricted stock units 555,984 — 555,984 351,668 Warrants 480,000 — 480,000 810,000 |
Investment Securities Available
Investment Securities Available-for-Sale (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Investments [Abstract] | |
Investment [Table Text Block] | The amortized cost, gross unrealized holding gains and losses, fair value of long-term investments, which are classified as available-for-sale, and fair value of short-term investments by major security type and class of security were as follows as of June 30, 2018 and December 31, 2017 (in thousands): Amortized Gross Gross Fair As of June 30, 2018 Available-for-sale: Foreign deposits $ 2,311 $ — $ — $ 2,311 Municipal bond 1,000 — — 1,000 $ 3,311 $ — $ — $ 3,311 Short-term investments: U.S. Treasury securities $ 6,231 $ — $ (2 ) $ 6,229 Certificates of deposit 439 — — 439 U.S. government funds 36,132 — — 36,132 $ 42,802 $ — $ (2 ) $ 42,800 Amortized Gross Gross Fair As of December 31, 2017 Available-for-sale: Foreign deposits $ 2,237 $ — $ — $ 2,237 Municipal bond 1,000 — — 1,000 $ 3,237 $ — $ — $ 3,237 Short-term investments: U.S. Treasury securities $ 5,783 $ — $ (4 ) $ 5,779 Certificates of deposit 690 1 — 691 U.S. government funds 31,117 — — 31,117 $ 37,590 $ 1 $ (4 ) $ 37,587 |
Available-for-sale Securities [Table Text Block] | Maturities of debt securities classified as available-for-sale were as follows (in thousands): June 30, 2018 Amortized Fair Available-for-sale: Due after one year through five years $ 2,311 $ 2,311 Due after five years through ten years 1,000 1,000 $ 3,311 $ 3,311 |
Fair Value (Tables)
Fair Value (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Fair Value Disclosures [Abstract] | |
Fair value, asset & liabilities measured on recurring basis [Table Text Block] | The following table summarizes, by major security type, the Company's assets that are measured at fair value on a recurring basis, and placement within the fair value hierarchy (in thousands): As of June 30, 2018 Fair Value Level 1 Level 2 Assets Restricted cash $ 1,400 $ 1,400 $ — Foreign deposits 2,311 2,311 — Municipal bond 1,000 — 1,000 Money market funds 45,420 45,420 — Total $ 50,131 $ 49,131 $ 1,000 As of December 31, 2017 Fair Value Level 1 Level 2 Assets Restricted cash $ 600 $ 600 $ — Foreign deposits 2,237 2,237 — Municipal bond 1,000 — 1,000 Money market funds 5,167 5,167 — Total $ 9,004 $ 8,004 $ 1,000 |
Claims Reserve (Tables)
Claims Reserve (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract] | |
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block] | Summarized below are the changes in the total liability for the Company's subscription business segment (in thousands): Six Months Ended June 30, Subscription 2018 2017 Reserve at beginning of year $ 11,059 $ 8,538 Veterinary invoices during the period related to: Current year 91,464 74,244 Prior years 119 (257 ) Total veterinary invoice expense 91,583 73,987 Amounts paid during the period related to: Current year 80,841 65,549 Prior years 9,256 7,138 Total paid 90,097 72,687 Non-cash expenses 333 229 Reserve at end of period $ 12,212 $ 9,609 The Company's reserve for the subscription business segment increased from $11.1 million at December 31, 2017 to $12.2 million at June 30, 2018 . This change was comprised of $91.6 million in expense recorded during the period less $90.1 million in payments of veterinary invoices. The $91.6 million in veterinary invoice expense incurred includes an adjustment of $0.1 million to the reserves relating to prior years, which is the result of ongoing analysis of recent payment trends. For the six months ended June 30, 2017 , the Company decreased prior year reserves by $0.3 million as a result of analysis of payment trends. Summarized below are the changes in total liability for the Company's other business segment (in thousands): Six Months Ended June 30, Other Business 2018 2017 Reserve at beginning of year $ 1,697 $ 983 Veterinary invoices during the period related to: Current year 10,589 6,337 Prior years (279 ) (128 ) Total veterinary invoice expense 10,310 6,209 Amounts paid during the period related to: Current year 8,916 5,217 Prior years 1,307 764 Total paid 10,223 5,981 Non-cash expenses — — Reserve at end of period $ 1,784 $ 1,211 The Company’s reserve for the other business segment increased from $1.7 million at December 31, 2017 to $1.8 million at June 30, 2018 . This change was comprised of $10.3 million in expense recorded during the period less $10.2 million in payments of veterinary invoices. The $10.3 million in veterinary invoice expense incurred includes a reduction of $0.3 million to the reserves relating to prior years, which is the result of ongoing analysis of recent payment trends. For the six months ended June 30, 2017 , the Company decreased prior year reserves by $0.1 million |
IBRN plus expected development on reported claims[Table Text Block] | In the following tables, the reserve for veterinary invoices for each segment is presented as the amount (in thousands) by year the veterinary invoice relates to, referred to as the year of occurrence. Subscription As of June 30, 2018 Year of Occurrence 2016 $ 386 2017 1,537 2018 10,289 $ 12,212 Other Business As of June 30, 2018 Year of Occurrence 2017 $ 110 2018 1,674 $ 1,784 |
Stock-based Compensation (Table
Stock-based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Stock-based compensation expense includes stock options, restricted stock awards, and restricted stock units granted to employees and non-employees and has been reported in the Company’s consolidated statements of operations depending on the function performed by the employee or non-employee. Stock-based compensation expense recognized in the consolidated statements of operations was as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Veterinary invoice expense $ 148 $ 89 $ 268 $ 159 Other cost of revenue 104 60 181 103 Technology and development 60 59 109 109 General and administrative 625 482 1,074 913 Sales and marketing 349 198 622 385 Total stock-based compensation $ 1,286 $ 888 $ 2,254 $ 1,669 As of June 30, 2018 , for all employees, the Company had 683,338 unvested stock options and 555,984 unvested restricted stock awards and restricted stock units that are expected to vest. Stock-based compensation expense of $4.3 million related to unvested stock options and $8.4 million related to unvested restricted stock awards and restricted stock units, each expected to be recognized over a weighted average period of approximately 2.3 |
Share-based Compensation, Stock Options, Activity [Table Text Block] | A summary of the Company's stock option activity is as follows: Number Of Options Weighted Average Exercise Price per Share Aggregate Intrinsic Value (in thousands) Outstanding as of December 31, 2017 4,006,399 $ 7.16 $ 88,578 Granted — — Exercised (262,967 ) 6.30 6,681 Forfeited (47,190 ) 15.44 Outstanding as of June 30, 2018 3,696,242 $ 7.12 $ 116,370 Exercisable as of June 30, 2018 3,008,570 $ 5.22 $ 100,432 As of June 30, 2018 , stock options outstanding and stock options exercisable had a weighted average remaining contractual life of 4.8 years and 4.1 |
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block] | A summary of the Company’s restricted stock award and restricted stock unit activity is as follows: Number of Weighted Average Unvested shares as of December 31, 2017 256,842 $ 4.77 Granted 323,358 27.87 Vested (12,603 ) 26.85 Forfeited (11,613 ) 28.36 Unvested shares as of June 30, 2018 555,984 $ 18.27 |
Stock-based Compensation Stockh
Stock-based Compensation Stockholder's Equity (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Class of Warrant or Right [Line Items] | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | During the six months ended June 30, 2018, 330,000 of the Company's outstanding warrants were exercised. As of June 30, 2018, warrants to purchase 480,000 shares of the Company's common stock at $10.00 |
Stock-based Compensation Follow
Stock-based Compensation Follow-on Public Offering (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Equity [Abstract] | |
Follow-on Public Offering, June 2018 [Table Text Block] | In the June 2018 follow-on public offering, the Company sold 2,090,909 shares of common stock (inclusive of 272,727 shares of common stock sold by the Company pursuant to the full exercise of the underwriters' option to purchase additional shares) at a price to the public of $33.00 per share. The Company received aggregate net proceeds of $65.9 million $3.0 million . The Company has a contingent commitment to purchase an additional $4.0 million of equity for eighteen months following the initial investment. In conjunction with the investment, the Company has extended a revolving line of credit with a maximum borrowing capacity of $2.5 million |
Segments (Tables)
Segments (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Segment Reporting [Abstract] | |
Revenue and Gross Profit from Segments [Table Text Block] | Revenue and gross profit of the Company’s segments were as follows (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Revenue: Subscription business $ 63,867 $ 52,641 $ 125,384 $ 102,870 Other business 9,525 5,634 17,768 10,134 73,392 58,275 143,152 113,004 Veterinary invoice expense: Subscription business 46,446 37,664 91,583 73,987 Other business 5,334 3,345 10,310 6,209 51,780 41,009 101,893 80,196 Other cost of revenue: Subscription business 5,887 4,927 11,764 9,850 Other business 3,372 1,988 6,078 3,452 9,259 6,915 17,842 13,302 Gross profit: Subscription business 11,534 10,050 22,037 19,033 Other business 819 301 1,380 473 12,353 10,351 23,417 19,506 Technology and development 2,298 2,322 4,462 4,725 General and administrative 4,610 4,245 9,068 8,257 Sales and marketing: Subscription business 5,614 4,309 11,465 8,350 Other business 88 63 175 111 5,702 4,372 11,640 8,461 Operating loss $ (257 ) $ (588 ) $ (1,753 ) $ (1,937 ) |
Revenue from External Customers by Geographic Areas [Table Text Block] | The following table presents the Company’s revenue by geographic region of the member (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 United States $ 59,431 $ 47,306 $ 115,440 $ 91,440 Canada 13,961 10,969 27,712 21,564 Total revenue $ 73,392 $ 58,275 $ 143,152 $ 113,004 |
Subsequent Events (Tables)
Subsequent Events (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Subsequent Events [Abstract] | |
Follow-on Public Offering, June 2018 [Table Text Block] | In the June 2018 follow-on public offering, the Company sold 2,090,909 shares of common stock (inclusive of 272,727 shares of common stock sold by the Company pursuant to the full exercise of the underwriters' option to purchase additional shares) at a price to the public of $33.00 per share. The Company received aggregate net proceeds of $65.9 million $3.0 million . The Company has a contingent commitment to purchase an additional $4.0 million of equity for eighteen months following the initial investment. In conjunction with the investment, the Company has extended a revolving line of credit with a maximum borrowing capacity of $2.5 million |
Building Purchase [Table Text Block] | n July 18, 2018, the Company purchased an equity interest, as a limited partner, in a privately held corporation for approximately $3.0 million . The Company has a contingent commitment to purchase an additional $4.0 million of equity for eighteen months following the initial investment. In conjunction with the investment, the Company has extended a revolving line of credit with a maximum borrowing capacity of $2.5 million |
Nature of Operations and Summ31
Nature of Operations and Summary of Significant Accounting Policies (Details) Narrative - USD ($) $ / shares in Units, $ in Thousands | 6 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
Organization and Basis of Presentation [Line Items] | ||
Common Stock, Shares, Issued | 2,090,909 | |
Common Stock, Shares, Issued to Underwriter | 272,727 | |
Shares Issued, Price Per Share | $ 33 | |
Proceeds from Issuance or Sale of Equity | $ 65,886 | $ 0 |
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax | $ 0 | $ 0 |
Net Loss per Share (Details) Sc
Net Loss per Share (Details) Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
Employee Stock Option [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 3,696,242 | 1,035,163 | 3,696,242 | 4,207,577 |
Restricted Stock Units (RSUs) [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 555,984 | 0 | 555,984 | 351,668 |
Warrant [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 480,000 | 0 | 480,000 | 810,000 |
Net Loss per Share Computation
Net Loss per Share Computation of Net Income (Loss) Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
Schedule of Earnings Per Share, Basic and Diluted [Line Items] | ||||
Net Income (Loss) Available to Common Stockholders, Basic | $ (377) | $ 411 | $ (1,857) | $ (1,071) |
Weighted Average Number of Shares Outstanding, Basic | 30,721,037 | 29,510,907 | 30,485,121 | 29,383,502 |
Earnings Per Share, Basic | $ (0.01) | $ 0.01 | $ (0.06) | $ (0.04) |
Weighted Average Number of Shares Outstanding, Diluted | 30,721,037 | 32,734,624 | 30,485,121 | 29,383,502 |
Earnings Per Share, Diluted | $ (0.01) | $ 0.01 | $ (0.06) | $ (0.04) |
Employee Stock Option [Member] | ||||
Schedule of Earnings Per Share, Basic and Diluted [Line Items] | ||||
Weighted Average Number Diluted Shares Outstanding Adjustment | 0 | 2,511,012 | 0 | 0 |
Restricted Stock Units (RSUs) [Member] | ||||
Schedule of Earnings Per Share, Basic and Diluted [Line Items] | ||||
Weighted Average Number Diluted Shares Outstanding Adjustment | 0 | 351,668 | 0 | 0 |
Warrant [Member] | ||||
Schedule of Earnings Per Share, Basic and Diluted [Line Items] | ||||
Weighted Average Number Diluted Shares Outstanding Adjustment | 0 | 361,037 | 0 | 0 |
Investment Securities (Details)
Investment Securities (Details) Investment Schedule - USD ($) $ in Thousands | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2017 |
Investment [Line Items] | |||
Available-for-sale securities, amortized cost | $ 3,311 | ||
Available-for-sale Securities, Gross Unrealized Gain | 0 | $ 0 | |
Available-for-sale Securities, Gross Unrealized Loss | 0 | 0 | |
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Amortized Cost Basis | $ 3,311 | 3,237 | |
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 3,311 | $ 3,311 | 3,237 |
Short-term investments, amortized cost | 42,802 | 37,590 | |
Short-term Investments, Gross Unrealized Holding Gains | 0 | 1 | |
Short-term investments, gross unrealized holding losses | (2) | (4) | |
Short-term Investments, fair value | 42,800 | 37,587 | |
Deposits [Member] | |||
Investment [Line Items] | |||
Available-for-sale securities, amortized cost | 2,311 | 2,237 | |
Available-for-sale Securities, Gross Unrealized Gain | 0 | 0 | |
Available-for-sale Securities, Gross Unrealized Loss | 0 | 0 | |
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 2,311 | 2,237 | |
Municipal Bonds [Member] | |||
Investment [Line Items] | |||
Available-for-sale securities, amortized cost | 1,000 | 1,000 | |
Available-for-sale Securities, Gross Unrealized Gain | 0 | 0 | |
Available-for-sale Securities, Gross Unrealized Loss | 0 | 0 | |
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 1,000 | 1,000 | |
U.S. Treasury securities | |||
Investment [Line Items] | |||
Short-term investments, amortized cost | 6,231 | 5,783 | |
Short-term Investments, Gross Unrealized Holding Gains | 0 | 0 | |
Short-term investments, gross unrealized holding losses | (2) | (4) | |
Short-term Investments, fair value | 6,229 | 5,779 | |
Certificates of deposit | |||
Investment [Line Items] | |||
Short-term investments, amortized cost | 439 | 690 | |
Short-term Investments, Gross Unrealized Holding Gains | 0 | 1 | |
Short-term investments, gross unrealized holding losses | 0 | 0 | |
Short-term Investments, fair value | 439 | 691 | |
US government debt securities | |||
Investment [Line Items] | |||
Short-term investments, amortized cost | 36,132 | 31,117 | |
Short-term Investments, Gross Unrealized Holding Gains | 0 | 0 | |
Short-term investments, gross unrealized holding losses | 0 | 0 | |
Short-term Investments, fair value | $ 36,132 | $ 31,117 |
Investment Securities (Detail35
Investment Securities (Details) Available-for-Sale - USD ($) $ in Thousands | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2017 |
Available-for-sale Securities [Abstract] | |||
Available-for-sale securities, debt maturities, year two through five, amortized cost basis | $ 2,311 | ||
Available-for-sale securities, debt maturities, year two through five, fair value | 2,311 | ||
Available-for-sale securities, debt maturities, year six through ten, amortized cost basis | 1,000 | ||
Available-for-sale securities, debt maturities, year six through ten, fair value | 1,000 | ||
Available-for-sale securities, amortized cost | 3,311 | $ 3,237 | |
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | $ 3,311 | $ 3,311 | $ 3,237 |
Fair Value (Details) Unobservab
Fair Value (Details) Unobservable - USD ($) | Jun. 30, 2018 | Mar. 31, 2018 | Dec. 31, 2017 |
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Restricted Cash | $ 1,400,000 | $ 600,000 | |
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 3,311,000 | $ 3,311,000 | 3,237,000 |
Assets, Fair Value Disclosure | 50,131,000 | 9,004,000 | |
Notes Receivable, Fair Value Disclosure | 2,500,000 | 2,500,000 | |
Fair Value, Inputs, Level 1 [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Assets, Fair Value Disclosure | 49,131,000 | 8,004,000 | |
Fair Value, Inputs, Level 2 [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Assets, Fair Value Disclosure | 1,000,000 | 1,000,000 | |
Cash and Cash Equivalents [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Restricted Cash | 1,400,000 | 600,000 | |
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 1 [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Restricted Cash | 1,400,000 | 600,000 | |
Cash and Cash Equivalents [Member] | Fair Value, Inputs, Level 2 [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Restricted Cash | 0 | 0 | |
Deposits [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 2,311,000 | 2,237,000 | |
Deposits [Member] | Fair Value, Inputs, Level 1 [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 2,311,000 | 2,237,000 | |
Deposits [Member] | Fair Value, Inputs, Level 2 [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 0 | 0 | |
Municipal bond | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Available-for-sale Securities, Debt Maturities, without Single Maturity Date, Fair Value | 1,000,000 | 1,000,000 | |
Available-for-sale Securities, Debt Maturities, Single Maturity Date | 1,000,000 | 1,000,000 | |
Municipal bond | Fair Value, Inputs, Level 1 [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Available-for-sale Securities, Debt Maturities, Single Maturity Date | 0 | 0 | |
Municipal bond | Fair Value, Inputs, Level 2 [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Available-for-sale Securities, Debt Maturities, Single Maturity Date | 1,000,000 | 1,000,000 | |
Money Market Funds [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Cash and Cash Equivalents, Fair Value Disclosure | 45,420,000 | 5,167,000 | |
Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Cash and Cash Equivalents, Fair Value Disclosure | 45,420,000 | 5,167,000 | |
Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member] | |||
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] | |||
Cash and Cash Equivalents, Fair Value Disclosure | $ 0 | $ 0 |
Debt (Details) Narrative
Debt (Details) Narrative - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2018 | Mar. 31, 2018 | |
Debt Disclosure [Abstract] | ||
Payments to Acquire Buildings | $ 55 | |
Line of Credit Facility, Maximum Borrowing Capacity | $ 50 | $ 30 |
Line of credit facility, interest rate description | greater of 4.5%, or 1.25% plus the prime rate | |
Line of Credit Facility, Interest Rate During Period | 6.25% | |
Line of Credit Facility, Ancillary Services and Letter of Credit | $ 4.5 | |
Restricted Cash and Cash Equivalents | 1.4 | |
Line of Credit Facility, Remaining Borrowing Capacity | 20.2 | |
Line of Credit Facility, Ancillary Services and Letter of Credit | 1.9 | |
Long-term Line of Credit | 18.8 | |
Line of Credit Financing Fee | $ 0.2 |
Commitment and Contingencies Ag
Commitment and Contingencies Agreement for the Purchase of Corporate Headquarter (Details) $ in Millions | 6 Months Ended |
Jun. 30, 2018USD ($)shares | |
Commitments and Contingencies Disclosure [Abstract] | |
Payments to Acquire Buildings | $ 55 |
Payments to Acquire Buildings, Shares | shares | 303,030 |
Operating Leases, Rent Expense | $ 1 |
Earnest Money Deposits | $ 3.3 |
Claims Reserve (Details) Claims
Claims Reserve (Details) Claims Loss Roll-forward - USD ($) $ in Thousands | 6 Months Ended | ||||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | |
Subscription business | |||||
Supplementary Insurance Information, by Segment [Line Items] | |||||
Claims Reserve | $ 12,212 | $ 9,609 | $ 11,059 | $ 8,538 | |
Current Year Claims Incurred | 91,464 | 74,244 | |||
Prior Year Claims Incurred | 119 | (257) | $ (300) | ||
Total Claims Incurred | 91,583 | 73,987 | |||
Current Year Claims Paid | 80,841 | 65,549 | |||
Prior Years Claims Paid | 9,256 | 7,138 | |||
Total Claims Paid | 90,097 | 72,687 | |||
Claims expense non-cash | 333 | 229 | |||
Claims Reserve by Loss Year | |||||
Incurred but Not Reported (IBNR) Claims Liability | 12,212 | ||||
Other business | |||||
Supplementary Insurance Information, by Segment [Line Items] | |||||
Claims Reserve | 1,784 | 1,211 | $ 1,697 | $ 983 | |
Current Year Claims Incurred | 10,589 | 6,337 | |||
Prior Year Claims Incurred | (279) | (128) | |||
Total Claims Incurred | 10,310 | 6,209 | |||
Current Year Claims Paid | 8,916 | 5,217 | |||
Prior Years Claims Paid | 1,307 | 764 | |||
Total Claims Paid | 10,223 | 5,981 | |||
Claims expense non-cash | 0 | $ 0 | |||
Claims Reserve by Loss Year | |||||
Incurred but Not Reported (IBNR) Claims Liability | 1,784 | ||||
Short-duration Insurance Contracts, Accident Year 2016 [Member] | Subscription business | |||||
Claims Reserve by Loss Year | |||||
Incurred but Not Reported (IBNR) Claims Liability | 386 | ||||
Short-duration Insurance Contracts, Accident Year 2017 [Member] | Subscription business | |||||
Claims Reserve by Loss Year | |||||
Incurred but Not Reported (IBNR) Claims Liability | 1,537 | ||||
Short-duration Insurance Contracts, Accident Year 2017 [Member] | Other business | |||||
Claims Reserve by Loss Year | |||||
Incurred but Not Reported (IBNR) Claims Liability | 110 | ||||
Shortduration insurance contracts for accident year 2018 [Member] | Subscription business | |||||
Claims Reserve by Loss Year | |||||
Incurred but Not Reported (IBNR) Claims Liability | 10,289 | ||||
Shortduration insurance contracts for accident year 2018 [Member] | Other business | |||||
Claims Reserve by Loss Year | |||||
Incurred but Not Reported (IBNR) Claims Liability | $ 1,674 |
Claims Reserve (Details) Narrat
Claims Reserve (Details) Narrative - USD ($) $ in Thousands | 6 Months Ended | ||||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | |
Subscription business | |||||
Supplementary Insurance Information, by Segment [Line Items] | |||||
Claims Reserve | $ 12,212 | $ 9,609 | $ 11,059 | $ 8,538 | |
Total Claims Incurred | 91,583 | 73,987 | |||
Total Claims Paid | 90,097 | 72,687 | |||
Prior Year Claims Incurred | 119 | (257) | $ (300) | ||
Other business | |||||
Supplementary Insurance Information, by Segment [Line Items] | |||||
Claims Reserve | 1,784 | 1,211 | $ 1,697 | $ 983 | |
Total Claims Incurred | 10,310 | 6,209 | |||
Total Claims Paid | 10,223 | 5,981 | |||
Prior Year Claims Incurred | $ (279) | $ (128) |
Claims Reserve Claims Reserve41
Claims Reserve Claims Reserve (Details) - USD ($) $ in Thousands | 6 Months Ended | ||||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | |
Subscription business | |||||
Liability for Claims and Claims Adjustment Expense [Line Items] | |||||
Claims Reserve | $ 12,212 | $ 9,609 | $ 11,059 | $ 8,538 | |
Current Year Claims Incurred | 91,464 | 74,244 | |||
Prior Year Claims Incurred | 119 | (257) | $ (300) | ||
Current Year Claims Paid | 80,841 | 65,549 | |||
Prior Years Claims Paid | 9,256 | 7,138 | |||
Total Claims Paid | 90,097 | 72,687 | |||
Claims expense non-cash | 333 | 229 | |||
Total Claims Incurred | 91,583 | 73,987 | |||
Other business | |||||
Liability for Claims and Claims Adjustment Expense [Line Items] | |||||
Claims Reserve | 1,784 | 1,211 | $ 1,697 | $ 983 | |
Current Year Claims Incurred | 10,589 | 6,337 | |||
Prior Year Claims Incurred | (279) | (128) | |||
Current Year Claims Paid | 8,916 | 5,217 | |||
Prior Years Claims Paid | 1,307 | 764 | |||
Total Claims Paid | 10,223 | 5,981 | |||
Claims expense non-cash | 0 | 0 | |||
Total Claims Incurred | $ 10,310 | $ 6,209 |
Stock-based Compensation (Detai
Stock-based Compensation (Details) Expense Category - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
Stock-based Compensation | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost | $ 1,286 | $ 888 | $ 2,254 | $ 1,669 |
Claims expense | ||||
Stock-based Compensation | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost | 148 | 89 | 268 | 159 |
Other Cost of Revenue | ||||
Stock-based Compensation | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost | 104 | 60 | 181 | 103 |
Technology and development | ||||
Stock-based Compensation | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost | 60 | 59 | 109 | 109 |
General and administrative | ||||
Stock-based Compensation | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost | 625 | 482 | 1,074 | 913 |
Sales and marketing | ||||
Stock-based Compensation | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost | 349 | $ 198 | $ 622 | $ 385 |
Restricted Stock Units (RSUs) [Member] | ||||
Stock-based Compensation | ||||
Employee share-based compensation arrangement and non-employee, weighted average remaining vesting period | 2 years 3 months | |||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 8,400 | $ 8,400 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | 555,984 | 555,984 | ||
Employee Stock Option [Member] | ||||
Stock-based Compensation | ||||
Employee share-based compensation arrangement and non-employee, weighted average remaining vesting period | 2 years 3 months 18 days | |||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 4,300 | $ 4,300 | ||
Employee share-based compensation arrangement by share-based payment award, options, nonvested, number of shares | 683,338 | 683,338 |
Stock-based Compensation (Det43
Stock-based Compensation (Details) Options Granted, Exercised and Forfeited - USD ($) $ / shares in Units, $ in Thousands | 6 Months Ended | |
Jun. 30, 2018 | Dec. 31, 2017 | |
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ||
Stock-based compensation, options, outstanding, number of shares | 3,696,242 | 4,006,399 |
Stock-based compensation, options, granted, number of options | 0 | |
Stock-based compensation, options, exercised | (262,967) | |
Stock-based compensation, options, forfeited | (47,190) | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number | 3,008,570 | |
Stock-based compensation, options, outstanding, weighted-average exercise price | $ 7.12 | $ 7.16 |
Stock-based compensation, options, granted, weighted-average exercise price | 0 | |
Stock-based compensation, options, exercised, weighted-average exercise price | 6.30 | |
Stock-based compensation, options, forfeited, weighted-average exercise price | 15.44 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ 5.22 | |
Stock-based compensation, options, outstanding, aggregate intrinsic value | $ 116,370 | $ 88,578 |
Stock-based compensation, options, exercised, aggregate intrinsic value | 6,681 | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value | $ 100,432 | |
Remaining contractual life, share-based payments, weighted average | 4 years 9 months 18 days | |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term | 4 years 1 month 6 days |
Stock-based Compensation Restri
Stock-based Compensation Restricted Stock Awards (Details) - Restricted Stock [Member] - $ / shares | 6 Months Ended | |
Jun. 30, 2018 | Dec. 31, 2017 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number | 555,984 | 256,842 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 323,358 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period | (11,613) | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period | (12,603) | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Grant Date Fair Value [Roll Forward] | ||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value | $ 18.27 | $ 4.77 |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | 27.87 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value | 28.36 | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value | $ 26.85 |
Stock-based Compensation Stoc45
Stock-based Compensation Stockholder Equity (Details) - USD ($) $ / shares in Units, $ in Thousands | 6 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
Stockholders' Equity Attributable to Parent [Abstract] | ||
Stock Issued During Period, Shares, New Issues | 2,090,909 | |
Redemption of warrants | 330,000 | |
Class of Warrant or Right, Outstanding | 480,000 | |
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 10 | |
Common Stock, Shares, Issued to Underwriter | 272,727 | |
Shares Issued, Price Per Share | $ 33 | |
Proceeds from Issuance or Sale of Equity | $ 65,886 | $ 0 |
Segments (Details) Business Seg
Segments (Details) Business Segment - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
Segment Reporting Information [Line Items] | ||||
Revenue | $ 73,392 | $ 58,275 | $ 143,152 | $ 113,004 |
Veterinary invoice expense | 51,780 | 41,009 | 101,893 | 80,196 |
Other cost of revenue | 9,259 | 6,915 | 17,842 | 13,302 |
Gross profit | 12,353 | 10,351 | 23,417 | 19,506 |
Sales and marketing | 5,702 | 4,372 | 11,640 | 8,461 |
Technology and Development | 2,298 | 2,322 | 4,462 | 4,725 |
General and administrative | 4,610 | 4,245 | 9,068 | 8,257 |
Operating loss | (257) | (588) | (1,753) | (1,937) |
Subscription business | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 63,867 | 52,641 | 125,384 | 102,870 |
Veterinary invoice expense | 46,446 | 37,664 | 91,583 | 73,987 |
Other cost of revenue | 5,887 | 4,927 | 11,764 | 9,850 |
Gross profit | 11,534 | 10,050 | 22,037 | 19,033 |
Sales and marketing | 5,614 | 4,309 | 11,465 | 8,350 |
Other business | ||||
Segment Reporting Information [Line Items] | ||||
Revenue | 9,525 | 5,634 | 17,768 | 10,134 |
Veterinary invoice expense | 5,334 | 3,345 | 10,310 | 6,209 |
Other cost of revenue | 3,372 | 1,988 | 6,078 | 3,452 |
Gross profit | 819 | 301 | 1,380 | 473 |
Sales and marketing | $ 88 | $ 63 | $ 175 | $ 111 |
Segments (Details) Revenue by G
Segments (Details) Revenue by Geography - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | |
Segment Reporting Information [Line Items] | ||||
Revenues | $ 73,392 | $ 58,275 | $ 143,152 | $ 113,004 |
CANADA | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | 13,961 | 10,969 | 27,712 | 21,564 |
UNITED STATES | ||||
Segment Reporting Information [Line Items] | ||||
Revenues | $ 59,431 | $ 47,306 | $ 115,440 | $ 91,440 |
Subsequent Events (Details)
Subsequent Events (Details) - USD ($) $ in Millions | 6 Months Ended | |
Jun. 30, 2018 | Jul. 18, 2018 | |
Subsequent Event [Line Items] | ||
Investment Company, Committed Capital | $ 4 | |
Increase (Decrease) in Notes Receivables | 2.5 | |
Payments to Acquire Buildings | $ 55 | |
Payments to Acquire Buildings, Shares | 303,030 | |
Subsequent Event [Member] | ||
Subsequent Event [Line Items] | ||
Purchase of Equity Interest | $ 3 |